BRISTOL MYERS SQUIBB PRESENTS POSITIVE RESULTS FROM PHASE 3 SCOUT-HCM TRIAL DEMONSTRATING EFFICACY AND SAFETY OF CAMZYOS (MAVACAMTEN) IN ADOLESCENTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)
BRISTOL-MYERS SQUIBB CO - SCOUT-HCM TRIAL MEETS PRIMARY ENDPOINT WITH SIGNIFICANT LVOT GRADIENT REDUCTION AT WEEK 28
BRISTOL-MYERS SQUIBB CO: RESULTS DEMONSTRATE POTENTIAL FOR CAMZYOS TO BE FIRST TARGETED PHARMACOLOGICAL THERAPY FOR TREATMENT OF OHCM IN ADOLESCENTS
BRISTOL-MYERS SQUIBB CO: SAFETY PROFILE OF CAMZYOS IN ADOLESCENTS WAS SIMILAR TO ESTABLISHED PROFILE IN ADULTS
Source text: ID:nBw4Zw9L8a
Further company coverage: BMY.N
((Reuters.Briefs@thomsonreuters.com;))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments